T2 Biosystems, Inc. (TTOO)

2.8400 +0.1000 (+3.65%) At close: 04:00PM EDT

T2 Biosystems, Inc.

101 Hartwell Avenue
Lexington, MA 02421
United States
781 761 4646
https://www.t2biosystems.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 113

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John J. Sperzel III, B.Sc.	President, CEO & Chairman	865.5k	N/A	1963
Mr. Michael Terrence Gibbs Esq.	Senior VP, General Counsel & Company Secretary	622.6k	N/A	1971
Ms. Kelley J. Morgan	Chief People Officer	N/A	N/A	1976
Mr. Brett A. Giffin	Chief Commercial Officer	N/A	N/A	1959
Dr. Roger Smith Ph.D.	Senior Vice President of Science Research & Development	N/A	N/A	1965

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Corporate governance

T2 Biosystems, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.